Non‐Motor Symptoms in Parkinson's Disease are Reduced by Nabilone

The objective of this study was to assess the efficacy and safety of nabilone, a synthetic tetrahydrocannabinol analogue, as a treatment for non‐motor symptoms (NMS) in Parkinson's disease (PD).

[1]  J. Brotchie,et al.  Cannabinoids reduce levodopa-induced dyskinesia in Parkinson’s disease: A pilot study , 2001, Neurology.

[2]  P. Castillo,et al.  Endocannabinoid Signaling and Synaptic Function , 2012, Neuron.

[3]  Penny F Whiting,et al.  Cannabinoids for Medical Use: A Systematic Review and Meta-analysis. , 2015, JAMA.

[4]  K. Desante,et al.  Pharmacokinetics, metabolism and drug-abuse potential of nabilone. , 1982, Cancer treatment reviews.

[5]  L. Chiou,et al.  Targeting the cannabinoid system for pain relief? , 2013, Acta anaesthesiologica Taiwanica : official journal of the Taiwan Society of Anesthesiologists.

[6]  G. Deuschl,et al.  Validation of the questionnaire for impulsive-compulsive disorders in Parkinson’s disease (QUIP) and the QUIP-rating scale in a German speaking sample , 2014, Journal of Neurology.

[7]  M. Pistis,et al.  Endocannabinoid Signaling in Midbrain Dopamine Neurons: More than Physiology? , 2007, Current neuropharmacology.

[8]  D. Lovinger,et al.  CB1 cannabinoid receptor inhibits synaptic release of glutamate in rat dorsolateral striatum. , 2001, Journal of neurophysiology.

[9]  J. Brotchie.  CB1 cannabinoid receptor signalling in Parkinson's disease. , 2003, Current opinion in pharmacology.

[10]  J. Jankovic,et al.  The therapeutic potential of cannabinoids for movement disorders , 2015, Movement disorders : official journal of the Movement Disorder Society.

[11]  W Poewe,et al.  Non‐motor symptoms in Parkinson’s disease , 2008, European journal of neurology.

[12]  D. Finn,et al.  High Times for Painful Blues: The Endocannabinoid System in Pain-Depression Comorbidity , 2015, The international journal of neuropsychopharmacology.

[13]  M. Okun,et al.  Medicinal Cannabis for Parkinson's Disease: Practices, Beliefs, and Attitudes Among Providers at National Parkinson Foundation Centers of Excellence , 2017, Movement disorders clinical practice.

[14]  T. Rudroff,et al.  Cannabis use in people with Parkinson's disease and Multiple Sclerosis: A web-based investigation. , 2017, Complementary therapies in medicine.

[15]  G. Tomlinson,et al.  Another face of placebo: The lessebo effect in Parkinson disease , 2014, Neurology.

[16]  R. Mechoulam,et al.  Cannabinoids provide neuroprotection against 6-hydroxydopamine toxicity in vivo and in vitro: Relevance to Parkinson's disease , 2005, Neurobiology of Disease.

[17]  J. Crippa,et al.  Cannabidiol can improve complex sleep‐related behaviours associated with rapid eye movement sleep behaviour disorder in Parkinson's disease patients: a case series , 2014, Journal of clinical pharmacy and therapeutics.

[18]  G. Stebbins,et al.  Assessing the non‐motor symptoms of Parkinson's disease: MDS‐UPDRS and NMS Scale , 2015, European journal of neurology.

[19]  Jacob Cohen.  Statistical Power Analysis for the Behavioral Sciences , 1969, The SAGE Encyclopedia of Research Design.

[20]  W. Poewe,et al.  Nabilone for non-motor symptoms of Parkinson’s disease: a randomized placebo-controlled, double-blind, parallel-group, enriched enrolment randomized withdrawal study (The NMS-Nab Study) , 2019, Journal of Neural Transmission.

[21]  P. Calabresi,et al.  Experimental Parkinsonism Alters Endocannabinoid Degradation: Implications for Striatal Glutamatergic Transmission , 2002, The Journal of Neuroscience.

[22]  R. L. Rosnow,et al.  Effect sizes for experimenting psychologists. , 2003, Canadian journal of experimental psychology = Revue canadienne de psychologie experimentale.

[23]  E. Růžička,et al.  Survey on cannabis use in Parkinson's disease: Subjective improvement of motor symptoms , 2004, Movement disorders : official journal of the Movement Disorder Society.

[24]  Jennifer J. Richler,et al.  Effect size estimates: current use, calculations, and interpretation. , 2012, Journal of experimental psychology. General.

[25]  L. DeLisi,et al.  Effects of Cannabis Use on Human Behavior, Including Cognition, Motivation, and Psychosis: A Review. , 2016, JAMA psychiatry.

[26]  R. Djaldetti,et al.  Cannabis (Medical Marijuana) Treatment for Motor and Non–Motor Symptoms of Parkinson Disease: An Open-Label Observational Study , 2014, Clinical neuropharmacology.

[27]  S. Dursun,et al.  Cannabidiol for the treatment of psychosis in Parkinson’s disease , 2009, Journal of psychopharmacology.

[28]  G. Bernardi,et al.  High endogenous cannabinoid levels in the cerebrospinal fluid of untreated Parkinson's disease patients , 2005, Annals of neurology.

[29]  Jacob Cohen.  The t Test for Means , 1977 .

[30]  Y. Baruch,et al.  Medical Cannabis in Parkinson Disease: Real-Life Patients' Experience , 2017, Clinical neuropharmacology.

[31]  J. Stamford,et al.  Drugs of abuse and Parkinson's disease , 2016, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[32]  Jeih-San Liow,et al.  Imaging and Quantitation of Cannabinoid CB1 Receptors in Human and Monkey Brains Using 18F-Labeled Inverse Agonist Radioligands , 2010, Journal of Nuclear Medicine.

[33]  S. Bhattacharyya,et al.  The effect of cannabis use on memory function: an update , 2013, Substance abuse and rehabilitation.

[34]  Daniel Weintraub,et al.  Update on treatments for nonmotor symptoms of Parkinson's disease—an evidence‐based medicine review , 2019, Movement disorders : official journal of the Movement Disorder Society.

[35]  D. Lovinger,et al.  Endocannabinoid Signaling Regulates Sleep Stability , 2016, PloS one.

[36]  K. Hill.  Medical Use of Cannabis in 2019. , 2019, JAMA.

[37]  Xia Zhang,et al.  Endocannabinoid system: Role in depression, reward and pain control (Review) , 2016, Molecular medicine reports.

[38]  S. Petrosino,et al.  Endocannabinoids and endocannabinoid-related mediators: Targets, metabolism and role in neurological disorders. , 2016, Progress in lipid research.

[39]  X. Mao,et al.  CB1 cannabinoid receptor induction in experimental stroke , 2000, Annals of neurology.

[40]  L Teare,et al.  Cannabis for dyskinesia in Parkinson disease , 2004, Neurology.

[41]  B. Galer,et al.  Impact of responder definition on the enriched enrollment randomized withdrawal trial design for establishing proof of concept in neuropathic pain , 2011, PAIN®.

[42]  W. Oertel,et al.  Risk factors for neurodegeneration in idiopathic rapid eye movement sleep behavior disorder: A multicenter study , 2015, Annals of neurology.

[43]  M. Haney,et al.  Chapter 85 – The Synthetic Analog of Δ9-Tetrahydrocannabinol (THC): Nabilone. Pharmacology and Clinical Application , 2017 .

[44]  R. Djaldetti,et al.  Pain in Extrapyramidal Neurodegenerative Diseases , 2017, The Clinical journal of pain.